Should a Patient Who Has Only Received PCV13 Receive Another Pneumococcal Vaccine?
Yes, patients who have received only PCV13 should receive an additional pneumococcal vaccine—specifically PCV20, PCV21, or PPSV23—administered at least 1 year after the PCV13 dose (or ≥8 weeks for those with immunocompromising conditions, cochlear implants, or CSF leaks). 1
Recommended Next Steps Based on Patient Age and Risk Status
For Adults ≥65 Years (Immunocompetent)
- Preferred approach: Administer a single dose of PCV20 or PCV21 ≥1 year after PCV13 1
- Alternative: PPSV23 can be given ≥1 year after PCV13 (or ≥8 weeks for high-risk conditions) 1
- If PCV20 or PCV21 is chosen, the pneumococcal vaccine series is complete—no additional doses needed 1
- If PPSV23 is chosen instead, the patient may later receive PCV20 or PCV21 ≥5 years after PPSV23 1
For Adults 19-64 Years with Immunocompromising Conditions
This includes chronic renal failure, immunodeficiency, HIV, malignancy, transplant, asplenia, or sickle cell disease 1:
- Preferred: PCV20 or PCV21 ≥1 year after PCV13 1
- Alternative: PPSV23 ≥8 weeks after PCV13, followed by consideration of PCV20/PCV21 ≥5 years later 1
- For cancer patients specifically, PCV20 can be given ≥1 year after PCV13 rather than PPSV23 2
For Adults 19-64 Years with Chronic Medical Conditions Only
This includes diabetes, chronic heart/lung/liver disease, alcoholism, or smoking 1:
- Administer PCV20, PCV21, or PPSV23 ≥1 year after PCV13 1
- The choice between these options is flexible, though newer conjugate vaccines (PCV20/PCV21) provide broader coverage
Key Clinical Considerations
Why not just repeat PCV13? The 2024 ACIP guidelines do not recommend repeating PCV13 itself 1. Instead, they recommend transitioning to higher-valency vaccines (PCV20 with 20 serotypes, PCV21 with 21 serotypes) or adding PPSV23 (covering 23 serotypes) to broaden protection beyond the original 13 serotypes.
Timing is critical: The minimum interval of 1 year between PCV13 and the next vaccine is important for optimal immune response 1. The exception is for high-risk patients (immunocompromised, cochlear implants, CSF leaks) who can receive PPSV23 as early as 8 weeks after PCV13 1.
Prior PPSV23 blunts response: If a patient received PPSV23 before PCV13, subsequent PCV responses are diminished 3, 4. This is why the conjugate vaccine should ideally come first.
Common Pitfalls to Avoid
- Don't leave PCV13-only patients unvaccinated: With only PCV13, patients lack coverage for important serotypes like 8, 10A, 11A, 12F, 15B, 22F, and 33F (in PCV20) or serotype 21 (in PCV21) 1
- Don't give vaccines too close together: Respect the 1-year interval for immunocompetent patients to optimize immune response 1
- Don't assume completion: PCV13 alone does not constitute a complete pneumococcal vaccine series under current guidelines 1
- Check vaccination history carefully: Many patients may have received childhood PCV7 or PCV13, which still requires adult vaccination 1
Special Population: Cancer Patients
For patients with cancer who received PCV13 only, the NCCN guidelines specifically recommend PCV20 ≥1 year after PCV13 as the preferred approach, noting that additional PPSV23 is not needed after PCV20 2.